1. Kandel et al. have identified oleic acid (18:1ω9 MUFA) as the long-sought-after endogenous ligand that binds the nuclear receptor TLX/NR2E1, which is known to regulate adult neurogenesis in the hippocampus.
2. Oleic acid can physically interact with the TLX ligand-binding domain and modulate TLX activity upon binding to it, leading to derepression or activation of TLX-responsive genes.
3. Treatment with oleic acid led to increased numbers of neural stem cells and newborn neurons in young and old mice, respectively, demonstrating its potential role in modulating neurogenesis through TLX.
The article is generally reliable and trustworthy, as it provides a comprehensive overview of Kandel et al.'s findings regarding oleic acid's role in regulating hippocampal neurogenesis as a TLX ligand. The authors provide evidence for their claims by citing relevant studies and experiments conducted by Kandel et al., such as molecular docking, biolayer interferometry, cotransfection of a TLX expression vector and a TLX-responsive luciferase reporter into HeLa cells, stereotactic injection of oleic acid into young and old mice, etc. Furthermore, they discuss potential implications of these findings for clinical trials for drugs targeting neurodegenerative diseases where neurogenesis has been shown to be dysregulated.
However, there are some potential biases present in the article that should be noted. For example, while the authors do mention possible risks associated with oleic acid treatment (such as its ability to partially derepress neurogenesis-related genes), they do not explore this topic further or provide any evidence for their claims regarding possible risks associated with oleic acid treatment. Additionally, while the authors do mention counterarguments (such as how many of the genes regulated by oleic acid are direct targets of TLX), they do not explore this topic further or provide any evidence for their claims regarding counterarguments. Finally, while the authors do discuss potential implications of these findings for clinical trials for drugs targeting neurodegenerative diseases where neurogenesis has been shown to be dysregulated, they do not explore this topic further or provide any evidence for their claims regarding potential implications for clinical trials.
In conclusion, while the article is generally reliable